179 related articles for article (PubMed ID: 36908770)
1. Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis.
Pipe SW; Trzaskoma B; Minhas M; Lehle M; Ko RH; Gao L; Mahlangu J; Kempton CL; Kessler CM; Kruse-Jarres R
Res Pract Thromb Haemost; 2023 Feb; 7(2):100077. PubMed ID: 36908770
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5).
Yang R; Wang S; Wang X; Sun J; Chuansumrit A; Zhou J; Schmitt C; Hsu W; Xu J; Li L; Chang T; Zhao X
Res Pract Thromb Haemost; 2022 Feb; 6(2):e12670. PubMed ID: 35284778
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials.
Klamroth R; Wojciechowski P; Aballéa S; Diamand F; Hakimi Z; Nazir J; Abad-Franch L; Lethagen S; Santagostino E; Tarantino MD
J Blood Med; 2021; 12():115-122. PubMed ID: 33664606
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies.
Mahlangu J; Jiménez-Yuste V; Ventriglia G; Niggli M; Barlera S; Hermans C; Lehle M; Chowdary P; Jew L; Windyga J; Frenzel L; Schmitt C; Castaman G; Pipe SW
Res Pract Thromb Haemost; 2024 Feb; 8(2):102364. PubMed ID: 38559572
[TBL] [Abstract][Full Text] [Related]
6. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
Négrier C; Mahlangu J; Lehle M; Chowdary P; Catalani O; Bernardi RJ; Jiménez-Yuste V; Beckermann BM; Schmitt C; Ventriglia G; Windyga J; d'Oiron R; Moorehead P; Koparkar S; Teodoro V; Shapiro AD; Oldenburg J; Hermans C
Lancet Haematol; 2023 Mar; 10(3):e168-e177. PubMed ID: 36716761
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Callaghan MU; Negrier C; Paz-Priel I; Chang T; Chebon S; Lehle M; Mahlangu J; Young G; Kruse-Jarres R; Mancuso ME; Niggli M; Howard M; Bienz NS; Shima M; Jiménez-Yuste V; Schmitt C; Asikanius E; Levy GG; Pipe SW; Oldenburg J
Blood; 2021 Apr; 137(16):2231-2242. PubMed ID: 33512413
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.
Reyes A; Révil C; Niggli M; Chebon S; Schlagmüller S; Flacke JP; Zortel M; Paz-Priel I; Asikanius E; Hampton R; Mahajan A; Schmidt E; Edwards SC
Curr Med Res Opin; 2019 Dec; 35(12):2079-2087. PubMed ID: 31355677
[No Abstract] [Full Text] [Related]
9. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste.
Donners AAMT; van der Zwet K; Rademaker CMA; Egberts TCG; Schutgens REG; Fischer K
Res Pract Thromb Haemost; 2023 Feb; 7(2):100074. PubMed ID: 36915864
[TBL] [Abstract][Full Text] [Related]
11. Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII.
Jonsson F; Schmitt C; Petry C; Mercier F; Frey N; Retout S
Clin Pharmacokinet; 2021 Jul; 60(7):931-941. PubMed ID: 33709296
[TBL] [Abstract][Full Text] [Related]
12. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.
Pipe SW; Collins P; Dhalluin C; Kenet G; Schmitt C; Buri M; Jiménez-Yuste V; Peyvandi F; Young G; Oldenburg J; Mancuso ME; Kavakli K; Kiialainen A; Deb S; Niggli M; Chang T; Lehle M; Fijnvandraat K
Blood; 2024 Apr; 143(14):1355-1364. PubMed ID: 38127586
[TBL] [Abstract][Full Text] [Related]
13. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
Mahlangu JN
BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
[TBL] [Abstract][Full Text] [Related]
14. Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single-center report.
Warren BB; Chan A; Manco-Johnson M; Branchford BR; Buckner TW; Moyer G; Gibson E; Thornhill D; Wang M; Ng CJ
Res Pract Thromb Haemost; 2021 Jul; 5(5):e12571. PubMed ID: 34377887
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks.
Kiialainen A; Adamkewicz JI; Petry C; Oldenburg J; Pipe SW; Young G; Mahlangu J; Lehle M; Niggli M; Castaman G; Jiménez-Yuste V; Shima M; Négrier C; Schmitt C
Res Pract Thromb Haemost; 2024 Jan; 8(1):102306. PubMed ID: 38282901
[TBL] [Abstract][Full Text] [Related]
16. Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3.
Callaghan MU; Asikanius E; Lehle M; Oldenburg J; Mahlangu J; Uguen M; Chebon S; Kruse-Jarres R; Jiménez-Yuste V; Shima M; Trask P; Kempton CL; Kessler CM; Levy GG; Peyvandi F
Res Pract Thromb Haemost; 2022 Aug; 6(6):e12782. PubMed ID: 36171959
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME
Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801
[TBL] [Abstract][Full Text] [Related]
18. Emicizumab for the prevention of bleeds in hemophilia A.
Mahlangu J
Expert Opin Biol Ther; 2019 Aug; 19(8):753-761. PubMed ID: 31150297
[No Abstract] [Full Text] [Related]
19. Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis.
Hermans C; Ventriglia G; Obaji S; Beckermann BM; Lehle M; Catalani O; d'Oiron R; Frenzel L
Res Pract Thromb Haemost; 2023 Nov; 7(8):102239. PubMed ID: 38193069
[TBL] [Abstract][Full Text] [Related]
20. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
